Johnson & Johnson sees global pharmaceutical sales jump

Share this article:
 Johnson & Johnson today reported worldwide pharmaceutical sales of $22.1 billion for the full year 2004, an increase of 13.4 percent. Domestic sales of pharmaceuticals increased 12.7 percent.
The company, which achieved total worldwide sales of  $47.3 billion last year (a 13.1 percent increase), attributed its strong pharmaceutical sales growth to the strong performances of Risperdal and Risperdal Consta, an antipsychotic medication. Risperdal, J&J's second-largest drug, achieved sales of roughly $1.5 billion in the U.S. last year, a gain of 18 percent.
Sales of Topamax, an antiepileptic and a treatment for the prevention of migraine headaches, rose 36 percent in the U.S. last year, while Remicade, a treatment for rheumatoid arthritis, achieved a 23 percent sales increase in the U.S.
Sales of Duragesic, a transdermal patch for chronic pain, rose 30 percent in the U.S.
"Each of our business segments -- pharmaceuticals, medical devices and diagnostics, and consumer products -- made important contributions to yet another strong year for Johnson & Johnson," chairman and chief executive William Weldon said in a statement.
J&J's net earnings in 2004 totaled $8.5 billion, increases of 18.2 percent.
J&J recently submitted new drug applications to the FDA for dapoxetine hydrochloride, a new treatment for premature ejaculation, and for Zarnestra (tipifarnib) for the treatment of elderly patients with newly diagnosed poor-risk acute myeloid leukemia.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.